Roche Holdings Ltd ADR (RHHBY)

$42.27 -0.20 (-0.47%)
Market Cap 270.25B
Revenue (ttm) 70.87B
Net Income (ttm) 9.40B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 14.64
Profit Margin 13.27%
Debt to Equity Ratio 0.96
Volume 2,209,100
Avg Vol 1,565,860
Day's Range N/A - N/A
Shares Out 6.36B
Stochastic %K 2%
Beta 0.47
Analysts Sell
Price Target $44.62

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
dogDazeSummer
dogDazeSummer Oct. 25 at 12:28 AM
@FlowerInTheCellar @MrCompassion I also like that RA has sold 4 companies to $ABBV in last 12 months. It’s sooooo clear that Peter has a direct line to CEO of Abbie. Now that both $AMGN $BIIB have their own C5aR inhibitors —-How can $RHHBY and $ABBV wander around naked & unable to battle inflammation without a black box? AAV, ARDS, Alzheimer’s, Dementia, Renal, Cancers (lung, thyroid, pancreatic), Dermatological, cardiac—-PG, HS, CSU- any 1 is $1B+ After biogen dropped up to $1B+ today for the c5ra axis, I officially drank the cool aid and align with Mr Compassions thesis. Why invest up to $1B for a drug thats years behind INF904? B/c it’s prolly worth $10B long term revenue. B/c INF904 is prolly worth $3B-5b today. Yes. Today. Won’t be surprised to see weekend news stories and open at $2-$3- still 1/4 of what Biogen committed to. We’re just getting started in this ….all time high $50
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 24 at 4:48 PM
$IFRX IMO this should be $2-$3 today based on $1B overall potential value $BIIB just ascribed. $AMGN is already in game with avacopan. $ABBV $RHHBY not yet. Someone please repost Tom comments (our CFO) when asked about funding INF904 P2b trials at Cantor conference. Part 2: “INF904’s clinical progress positions IFRX ahead of announced collaboration. Mechanistically, both Biogen’s and InflaRx’s programs aim to attenuate the same receptor axis (C5aR1), which mediates neutrophil recruitment and activation downstream of complement component C5a. While Vanqua Bio’s molecule remains pre-IND, INF904 is already in phase 2 with POC data expected imminently. Recall, INF904 has shown optimized profile in phase 1 including no DLTs, superior systemic exposure, durable target coverage, cleaner drug-drug interaction profile, and consistent >90% ex vivo inhibition of C5a activity positions.”
2 · Reply
CedarPark
CedarPark Oct. 23 at 7:45 PM
$RHHBY if I owned this, I would sell and buy $TGTX for the better MS drug and for much faster/growth potential. Also a future buyout of TGTX very possible..
0 · Reply
ern1in
ern1in Oct. 23 at 3:58 PM
$TGTX / $RHHBY 👁
0 · Reply
JinxyBio
JinxyBio Oct. 23 at 8:39 AM
$TGTX $RHHBY Ocrevus sales in the US grew by only 1% in Q3 2025, and this data INCLUDES Ocrevus-SC as well as Ocrevus-IV. I bet if we saw a breakdown, Ocrevus-IV would be NEGATIVE (in part due to growth of Briumvi). Ocrevus-SC has treated 12.5k patients globally
2 · Reply
ern1in
ern1in Oct. 22 at 9:22 PM
$RHHBY
0 · Reply
DmcMouse
DmcMouse Oct. 22 at 9:10 PM
$LMDX $RHHBY $ELECTRADX do the right thing here...........
1 · Reply
dogDazeSummer
dogDazeSummer Oct. 22 at 11:18 AM
$IFRX Lots of cash on sidelines for big pharmaceutical entities according to new data out from Leerink: Not to mention $XBI flying 52wk highs creating daily increase in currency. Cash + Currency does imply M&A. $PFE $RHHBY $AZN
0 · Reply
ZacksResearch
ZacksResearch Oct. 21 at 2:47 PM
FDA clears $RHHBY's Gazyva's label expansion for lupus nephritis — what this means for investors The FDA's regulatory filing approval, based on the phase III REGENCY study, showed nearly half of the patients achieved complete renal response, highlighting robust results and a unique mechanism of action. Year to date, RHHBY shares have surged 26.3%, outperforming the industry's 5.1% growth. Discover what this means for Roche's future prospects 👉 https://www.zacks.com/stock/news/2773009/roches-gazyva-secures-fda-nod-for-label-expansion-in-lupus-nephritis?cid=sm-stocktwits-2-2773009-body-16863&ADID=SYND_STOCKTWITS_TWEET_2_2773009_BODY_16863
0 · Reply
ZacksResearch
ZacksResearch Oct. 21 at 1:47 PM
$RHHBY gets FDA green light for Gazyva label expansion The approval adds lupus nephritis to its treatment list — giving patients a faster, more convenient option and strengthening Roche’s immunology footprint. Full story here 👉 https://www.zacks.com/stock/news/2773009/roches-gazyva-secures-fda-nod-for-label-expansion-in-lupus-nephritis?cid=sm-stocktwits-2-2773009-teaser-16848&ADID=SYND_STOCKTWITS_TWEET_2_2773009_TEASER_16848
0 · Reply
Latest News on RHHBY
No data available.
dogDazeSummer
dogDazeSummer Oct. 25 at 12:28 AM
@FlowerInTheCellar @MrCompassion I also like that RA has sold 4 companies to $ABBV in last 12 months. It’s sooooo clear that Peter has a direct line to CEO of Abbie. Now that both $AMGN $BIIB have their own C5aR inhibitors —-How can $RHHBY and $ABBV wander around naked & unable to battle inflammation without a black box? AAV, ARDS, Alzheimer’s, Dementia, Renal, Cancers (lung, thyroid, pancreatic), Dermatological, cardiac—-PG, HS, CSU- any 1 is $1B+ After biogen dropped up to $1B+ today for the c5ra axis, I officially drank the cool aid and align with Mr Compassions thesis. Why invest up to $1B for a drug thats years behind INF904? B/c it’s prolly worth $10B long term revenue. B/c INF904 is prolly worth $3B-5b today. Yes. Today. Won’t be surprised to see weekend news stories and open at $2-$3- still 1/4 of what Biogen committed to. We’re just getting started in this ….all time high $50
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 24 at 4:48 PM
$IFRX IMO this should be $2-$3 today based on $1B overall potential value $BIIB just ascribed. $AMGN is already in game with avacopan. $ABBV $RHHBY not yet. Someone please repost Tom comments (our CFO) when asked about funding INF904 P2b trials at Cantor conference. Part 2: “INF904’s clinical progress positions IFRX ahead of announced collaboration. Mechanistically, both Biogen’s and InflaRx’s programs aim to attenuate the same receptor axis (C5aR1), which mediates neutrophil recruitment and activation downstream of complement component C5a. While Vanqua Bio’s molecule remains pre-IND, INF904 is already in phase 2 with POC data expected imminently. Recall, INF904 has shown optimized profile in phase 1 including no DLTs, superior systemic exposure, durable target coverage, cleaner drug-drug interaction profile, and consistent >90% ex vivo inhibition of C5a activity positions.”
2 · Reply
CedarPark
CedarPark Oct. 23 at 7:45 PM
$RHHBY if I owned this, I would sell and buy $TGTX for the better MS drug and for much faster/growth potential. Also a future buyout of TGTX very possible..
0 · Reply
ern1in
ern1in Oct. 23 at 3:58 PM
$TGTX / $RHHBY 👁
0 · Reply
JinxyBio
JinxyBio Oct. 23 at 8:39 AM
$TGTX $RHHBY Ocrevus sales in the US grew by only 1% in Q3 2025, and this data INCLUDES Ocrevus-SC as well as Ocrevus-IV. I bet if we saw a breakdown, Ocrevus-IV would be NEGATIVE (in part due to growth of Briumvi). Ocrevus-SC has treated 12.5k patients globally
2 · Reply
ern1in
ern1in Oct. 22 at 9:22 PM
$RHHBY
0 · Reply
DmcMouse
DmcMouse Oct. 22 at 9:10 PM
$LMDX $RHHBY $ELECTRADX do the right thing here...........
1 · Reply
dogDazeSummer
dogDazeSummer Oct. 22 at 11:18 AM
$IFRX Lots of cash on sidelines for big pharmaceutical entities according to new data out from Leerink: Not to mention $XBI flying 52wk highs creating daily increase in currency. Cash + Currency does imply M&A. $PFE $RHHBY $AZN
0 · Reply
ZacksResearch
ZacksResearch Oct. 21 at 2:47 PM
FDA clears $RHHBY's Gazyva's label expansion for lupus nephritis — what this means for investors The FDA's regulatory filing approval, based on the phase III REGENCY study, showed nearly half of the patients achieved complete renal response, highlighting robust results and a unique mechanism of action. Year to date, RHHBY shares have surged 26.3%, outperforming the industry's 5.1% growth. Discover what this means for Roche's future prospects 👉 https://www.zacks.com/stock/news/2773009/roches-gazyva-secures-fda-nod-for-label-expansion-in-lupus-nephritis?cid=sm-stocktwits-2-2773009-body-16863&ADID=SYND_STOCKTWITS_TWEET_2_2773009_BODY_16863
0 · Reply
ZacksResearch
ZacksResearch Oct. 21 at 1:47 PM
$RHHBY gets FDA green light for Gazyva label expansion The approval adds lupus nephritis to its treatment list — giving patients a faster, more convenient option and strengthening Roche’s immunology footprint. Full story here 👉 https://www.zacks.com/stock/news/2773009/roches-gazyva-secures-fda-nod-for-label-expansion-in-lupus-nephritis?cid=sm-stocktwits-2-2773009-teaser-16848&ADID=SYND_STOCKTWITS_TWEET_2_2773009_TEASER_16848
0 · Reply
aletz
aletz Oct. 21 at 1:18 PM
$ALGS all the antigens have not rebounded significantly and stayed almost the same level it left after stopping taking pevy, absolutely ground breaking compared to the current standard of care. Big pharmas will be watching very closely, but ALGS has no interest of letting pevy go now. $GSK $RHHBY $GILD
1 · Reply
Quantumup
Quantumup Oct. 21 at 12:18 PM
H.C. Wainwright reiterated $VRDN Buy/$34 $DHTRF $RHHBY H.C. Wainwright said in its note:
0 · Reply
Quantumup
Quantumup Oct. 20 at 7:14 PM
Truist⬇️ $SRRK 's PT to $44 from $54, reiterated at Buy, and said KOL feedback & mgmt checks provide addn'l timeline clarity; $BIIB $RHHBY $NVS Truist added: Following the recent CRL (see our prior note here), OAI to the Catalent site and due-diligence around timelines, we remain buyers of SRRK and are updating our PT to $44/sh (prev $54) to reflect updated timelines for apitegromab launch. Based on feedback from several regulatory KOLs, a closer look at prior CRL resolution timelines, and conversations with SRRK management, we note a range of potential scenarios and we now assume 1H2027 launch. Earlier approval would be upside to our estimates. We remain positive on SRRK given apitegromab has limited regulatory risk, limited clinical trial risk (+ve Ph3 data), and limited/no competition, in our view.
0 · Reply
Quantumup
Quantumup Oct. 20 at 5:58 PM
Needham⬆️ $CELC's PT to $95 from $70, reiterated at Buy, and said that it considers updated gedatolisib results from the PIK3CA wild-type cohort of the pivotal VIKTORIA-1 study as further de-risking and potentially practice-changing—thinks a lack of PFS benefit observed for $RHHBY's oral SERD giredestrant in ESR1 WT patients removes an overhang on CELC. $PFE $AZN
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 20 at 1:26 PM
$IFRX Whats a Win? Current standard-of-care efficacy CSU, ~50-60% of patients respond partially to omalizumab (Xolair) $RHHBY but complete control is rare (<40%). Also why Roche often mentioned as a buyout. In HS, adalimumab $ABBV achieves HiSCR (primary endpoint) in ~50% at week 12, but placebo rates are ~25-30%, leaving high unmet need. Also why Abbie often mentioned as buyout candidate. In CSU, Historical Phase 2 benchmarks: Barzolvolimab $CLDX hit rapid UAS7 reductions in >50% with good tolerability; EVO756 showed 30% complete response at week 4. No yet approved. A "win" for $IFRX would mean clinically meaningful improvements over baseline, with rapid onset (e.g., by week 4) to highlight the oral, non-immunosuppressive profile. Even 25-35% responders with dose-dependent signals would signal upside, as it proves C5a inhibition works in antihistamine-refractory patients. **Differentiated MOA is significantly needed with no 1 drug doing the trick** Remember $MLTX ?
0 · Reply
Quantumup
Quantumup Oct. 17 at 7:14 PM
Jefferies reiterated $VRDN at a Buy-$44, and said that $RHHBY's results remove key comp pressure and position '003 as the leading Q4W+ SubQ therapy for TED after Roche's mixed Phase 3 results for its IL-6mAb Satralizumab in thyroid eye diseases—one pivotal trial didn't hit the primary endpoint while the other showed efficacy meaningfully weaker than $VRDN's Veligrotug.
0 · Reply
dogDazeSummer
dogDazeSummer Oct. 17 at 12:08 AM
@morgueana actually $RHHBY and $IFRX make an interesting combination and likely “already are friends.” Wld u think Inflarx would file this patent with first getting approval from Roche? https://patents.justia.com/patent/12180274
1 · Reply
MHuntswollen
MHuntswollen Oct. 16 at 11:04 PM
$ALT This turd is getting flushed again. So many companies like $NVO , $RHHBY, $GSK, and $MDGL are so further ahead in the mash race and already have approved products. Glad I'm done woth this P.O.S.!
6 · Reply
DmcMouse
DmcMouse Oct. 15 at 2:35 PM
$LMDX $RHHBY Is gonna make billions. Pay us we need a law suit or something this is really dirty how we're getting done. Someone here's gotta know someone with some reach and DOGE or something im sure some of us know SOMEBODY with some power!!!! Make it right I know your on here!!!
1 · Reply
ZacksResearch
ZacksResearch Oct. 15 at 12:46 PM
Big Pharma's M&A spree in metabolic diseases — what's driving the shift? 💊 $PFE, $NVO, and $RHHBY are diving into the obesity and metabolic disease space with multi-billion-dollar deals. This move marks a pivot from oncology to metabolic and cardio-metabolic diseases as areas with strong growth potential. 🚀 Discover the full strategy behind these acquisitions 👉 https://www.zacks.com/stock/news/2769007/pharma-ma-activity-picks-up-pace-what-does-it-signal-for-2026?cid=sm-stocktwits-2-2769007-body-16102&ADID=SYND_STOCKTWITS_TWEET_2_2769007_BODY_16102
0 · Reply
ZacksResearch
ZacksResearch Oct. 15 at 11:46 AM
Big Pharma’s deal frenzy is back — and it’s heating up fast. 💥 $PFE, $NVO, and $RHHBY are ramping up M&A targeting obesity and metabolic diseases, signaling a renewed push for growth heading into 2026. Find out what this surge could mean for the sector’s next big winners 👉 https://www.zacks.com/stock/news/2769007/pharma-ma-activity-picks-up-pace-what-does-it-signal-for-2026?cid=sm-stocktwits-2-2769007-teaser-16100&ADID=SYND_STOCKTWITS_TWEET_2_2769007_TEASER_16100
0 · Reply
DrIsaaac
DrIsaaac Oct. 13 at 7:39 PM
$RHHBY
0 · Reply